REDWOOD CITY, Calif., Oct. 30 OncoMed Pharmaceuticals, acompany developing novel therapeutics that target cancer stem cells, todayannounced the appointment of William D. Waddill to the position of Senior VicePresident and Chief Financial Officer. Mr. Waddill will be responsible forfinance and administration, reporting directly to Paul Hastings, OncoMed'sPresident and Chief Executive Officer.
"We are pleased to add Will's extensive finance experience in the lifescience industry to OncoMed," said Mr. Hastings. "Will has a proven trackrecord of financing and capitalizing on the scientific work of some of themost successful companies in our industry, and his insights will be invaluableas we move our company forward. He is a superb addition to our talented andveteran team."
Mr. Waddill brings more than 16 years of life science experience directingfundraising, financial operations and strategic analysis at numerousventure-backed and publicly-held life science companies. Most recently, Mr.Waddill held the position of Senior Vice President, Chief Financial Officer atIlypsa, Inc., where he was responsible for all corporate financial matters,most notably the plan that led to a $420 million acquisition by Amgen, Inc.Previously, he served as the principal of Square One Finance, a financialconsulting business, managing the finances of 34 biotechnology companies,including eight that are currently public and six that have been acquired.Prior, Mr. Waddill held positions at Exelixis, Inc., most recently as SeniorDirector, Finance, and served as CFO of Medical Science Partners, a venturecapital firm in Boston. He received a BS in accounting from the University ofIllinois at Chicago, and certification as a public accountant after work atPricewaterhouseCoopers and Deloitte and Touche.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is discovering and developing novel therapeuticstargeting cancer stem cells, the cells believed to be capable of driving tumorgrowth, recurrence and metastases. The company has established a library ofantibodies to cancer stem cell proteins for the treatment of solid tumors suchas breast, colon, prostate, and lung cancers. The company is a leader incancer stem cell research and the identification of novel cancer stem celltargets.
OncoMed's investors include Latterell Venture Partners, US VenturePartners, Morgenthaler Ventures, the Vertical Group, Adams Street Partners,DeNovo Ventures and Bay Partners. Information can also be found at thecompany's website http://www.oncomed.com.
SOURCE OncoMed Pharmaceuticals